0001415889-24-004666.txt : 20240221
0001415889-24-004666.hdr.sgml : 20240221
20240221173806
ACCESSION NUMBER: 0001415889-24-004666
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240216
FILED AS OF DATE: 20240221
DATE AS OF CHANGE: 20240221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LOUMEAU ERIC J
CENTRAL INDEX KEY: 0001239648
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37985
FILM NUMBER: 24661254
MAIL ADDRESS:
STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS
STREET 2: 4435 EASTGATE MALL STE.400
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ANAPTYSBIO, INC
CENTRAL INDEX KEY: 0001370053
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 203828755
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-362-6295
MAIL ADDRESS:
STREET 1: 10770 WATERIDGE CIRCLE, SUITE 210
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYSBIO INC
DATE OF NAME CHANGE: 20080828
FORMER COMPANY:
FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC
DATE OF NAME CHANGE: 20060724
4
1
form4-02212024_100259.xml
X0508
4
2024-02-16
0001370053
ANAPTYSBIO, INC
ANAB
0001239648
LOUMEAU ERIC J
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO
CA
92121
false
true
false
false
CHIEF LEGAL OFFICER
1
Common Stock
2024-02-16
4
M
0
5000
14.02
A
8240
D
Common Stock
2024-02-16
4
S
0
5000
25
D
3240
D
Employee Stock Option (right to buy)
14.02
2024-02-16
4
M
0
5000
0
D
2029-12-05
Common Stock
5000
78000
D
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated September 15, 2023.
The stock option vested and is exercisable as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.
In addition to the remaining options to purchase 78,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 355,310 shares of common stock, which options vest according to their terms.
/s/ Eric Loumeau
2024-02-21